French pharma outfit Pierre Fabre has teamed up with Indian biotech Aurigene to get its hands on a PD-1 checkpoint modulator, following a burgeoning trend in cancer drug development.
Resistance to antibacterials is fast becoming one of the most urgent public health problems, especially since the pipeline for new antibiotics largely has dried after Big Pharma's retreat from the field in recent years.
AstraZeneca's biologics arm MedImmune has tapped the University of California, San Francisco for a three-year drug discovery and development partnership.
MedImmune, AstraZeneca's biologics arm, had inked a three-year agreement with the University of California, San Francisco, tapping the school's roster of scientists with hopes of finding promising projects across a bevy of disease areas.
AstraZeneca is again turning its back on some projects developed alongside Targacept, handing back several preclinical assets but holding onto a once-promising Alzheimer's disease treatment that may have some use in another indication.
Two of the biggest players in Brazil's diagnostics industry are likely to confront major changes in the coming months--both worth noting as global competitors seek to enter one of the largest emerging markets around.
Pharma giant AstraZeneca has pulled the plug on a fleet of its in-development drugs but let live a rheumatoid arthritis treatment being co-developed with Chinese CRO giant WuXi PharmaTech.
The U.K.'s Wellcome Trust is putting up about $4.1 million to fund a collaboration between CRO Selcia and Edinburgh University, under which the two will develop new treatments for sleeping sickness.
With drug-resistant tuberculosis on the rise worldwide, the nonprofit Critical Path Institute has won an $11.8 million grant from the Bill & Melinda Gates Foundation to help speed development of new, much-needed TB drugs.
Last week Novartis' vaccine unit posted yet another operating loss, extending its streak in the red to four years. Yet despite its well-known, long-term problems, suitors are reportedly circling the unit, with the potential of Bexsero and Menveo likely to be a factor attracting potential buyers.